RESUMEN
@#[摘 要] 目的：探讨靶向融合肽IL-4Rα-lytic对卡波西肉瘤相关疱疹病毒（KSHV）阳性原发性渗出性淋巴瘤（PEL）细胞的体内外杀伤作用及其安全性。方法：应用MTT法检测IL-4Rα-lytic对KSHV阳性PEL细胞BCBL-1和BCP-1的杀伤能力。通过FCM检测IL-4Rα-lytic诱导KSHV阳性PEL细胞凋亡的情况。建立BCBL-1细胞小鼠移植瘤模型，连续3周（3次/周）腹腔注射IL-4Rα-lytic后，通过活体生物发光成像技术评估IL-4Rα-lytic对小鼠体内BCBL-1细胞移植瘤的抑制效果，并通过H-E染色和全血分析法检测其毒副作用。结果：靶向融合肽IL-4Rα-lytic在体外对两种KSHV阳性PEL细胞BCBL-1和BCP-1均有选择性杀伤作用（均P<0.01），并且可以在短时间内发挥杀伤作用（均P<0.01）。靶向融合肽IL-4Rα-lytic可诱导KSHV阳性PEL细胞BCBL-1和BCP-1凋亡（均P<0.05）。靶向融合肽IL-4Rα-lytic显著抑制BCBL-1细胞小鼠移植瘤的生长，与对照组比较差异具有统计学意义（P<0.05），并且无明显的器官毒性（均P>0.05），同时不会造成体质量异常（P>0.05）。结论：靶向融合肽IL-4Rα-lytic在体内外均显著抑制KSHV阳性PEL细胞的生长，且无明显毒副作用，有望为PEL的治疗提供一种新的治疗方案。
RESUMEN
Asthma is a chronic allergic inflammatory disease of lung. The initiation and progression of asthma is dependent on the cytokines interleukin (IL) -4 and IL-13 acting through related receptor complexes. Disease pathogenesis is effected by intracellular signaling pathways that couple primarily to specific motifs within the intracellular domain of the IL-4 receptor alpha chain (IL-4R alpha), a subunit that is common to the IL-4 and IL-13 receptor complexes. Neutralizing anti-cytokine strategies have proven to be highly successful on dissecting relevant effector pathways in experimental allergic disease, and are now entering clinical trials in human allergic disorders. Although there have been only a few clinical studies on the effects of cytokine modulators in asthma, this line of research and development appears promising.